Proactiveinvestors interviews Bob Proulx on what FDA’s designation of MagSense® imaging as a “breakthrough device” means for the company and its investors:
https://youtu.be/X4HLKyIl6Zo
Executive Chairman Bob Proulx on Pitt Street Research’s Stocks Down Under Podcast: Getting ready for a Phase 2 Study
August 21, 2025
Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks